Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

The Board of Laekna, Inc. is pleased to announce the consolidated annual results of the Group for the year ended December 31, 2025, together with comparative figures for the year ended December 31, 2024, as follows.

In this announcement, "we" and "our" refer to the Company and where the context otherwise requires, the Group. Certain amounts and percentage figures included in this announcement have been subject to rounding adjustments or have been rounded to one or two decimal places. Any discrepancies in any table, chart or elsewhere between totals and sums of amounts listed therein are due to rounding issues.

BUSINESS HIGHLIGHTS

During the year ended December 31, 2025, the Company achieved significant progress across its drug candidate pipeline and business operations. Key milestones and accomplishments include:

Advancing the Clinical Trials

LAE102 in Obesity, Phase I

LAE102 is our internally discovered monoclonal antibody against ActRIIA. Blocking Activin-ActRII pathway could promote muscle regeneration and reduce fat mass, positioning LAE102 as a promising drug candidate for muscle-preserving weight control.

In January 2025, the Group announced positive results from the Phase I single ascending dose study (the "**SAD Study**") of LAE102 for the treatment of obesity. The study enrolled 40 participants in Part A (IV) and 24 participants in Part B (SC). All participants were healthy volunteers and completed the study as designed. Overall, LAE102 was well tolerated following a single IV or SC dose. No serious adverse events or treatment emergent adverse events ("**TEAEs**") leading to discontinuation of treatment were reported. The majority of the TEAEs were mild laboratory test abnormalities, which were asymptomatic and did not require medical intervention. There was no reported case of diarrhea. Activin A levels increased rapidly within 24 hours following a single intravenous or subcutaneous dose of LAE102. The duration of elevated Activin A levels was dose-dependent. In the high-dose groups, 2-to-3-fold increases above baseline were maintained through 28 days post-administration, indicating prolonged pathway blockade. The robust PK/PD correlation suggests potential efficacy and supports further clinical development of LAE102 in overweight and obese populations, which established a solid foundation for the Phase I multiple ascending dose study (the "**MAD Study**"). The detailed study results were presented at the 85th scientific sessions of the American Diabetes Association ("**ADA**") in June 2025.

The Group had commenced subject recruitment for the Phase I MAD Study of LAE102 by the end of March 2025. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in overweight/obese subjects. The MAD Study enrolled overweight/obese subjects with an average BMI of 29.4 kg/m^2, given weekly subcutaneous injections for 5 doses. The preliminary results demonstrated an encouraging trend towards lean body mass increase and fat mass reduction. At week 5, the LAE102 6 mg/kg group exhibited a 1.7% increase in mean lean body mass and a 2.2% reduction in mean fat mass compared to the baseline. Adjusted from the placebo control group, the mean lean body mass is increased by 4.6%, whereas the mean fat mass is reduced by 3.6%. Consistent with the prior Phase I SAD Study of LAE102, the MAD Study demonstrated a well-tolerated safety profile, with no serious adverse events reported. Majority of TEAEs were mild (grade 1) and transient lab test abnormality. There was no diarrhea, muscle spasm or acne reported. The safety results were consistent with the known safety profile and no new safety signals were observed. LAE102 serum concentration reached steady state after 5 weekly subcutaneous injections and PK profile was consistent with its SAD Study. The robust PK/PD correlation further demonstrates the potential efficacy of LAE102 in overweight and obese population.

Following the positive one-month results observed in the early MAD study, a pre-planned Phase I multiple dose expansion study (the "**Multiple Dose Expansion Study**") was initiated to further evaluate the efficacy and safety profile of LAE102 over a longer treatment duration. In December 2025, the Group commenced subject recruitment for this study and dosed the first participant. The Phase I Multiple Dose Expansion Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in overweight/obese subjects. Total 60 subjects were enrolled and randomized into LAE102 or placebo for a 6-month treatment.

In March 2026, the Group announced successful completion, in collaboration with Eli Lilly and Company, of the Phase I single ascending dose study (the "**U.S. SAD Study**") of LAE102 in the U.S. Consistent with the prior safety profile of LAE102, the U.S. SAD Study demonstrated a well-tolerated safety profile, with no serious adverse events reported. The U.S. SAD Study showed encouraging trends in body composition improvements following administration of a single dose. Dose-dependent effects on lean body mass increase and fat mass reduction were observed. On Day 29 following a single dose of LAE102, the group with the highest exposure exhibited a 5.06% increase in mean lean body mass from baseline (placebo group has 1.34% reduction from baseline) and a 0.12% decrease in mean fat mass from baseline (placebo group has 2.11% increase from baseline). These positive results added to a growing body of data supporting LAE102 as a therapeutic approach to obesity.

Laekna team has accumulated tremendous experience and extensive knowhow in this specific field and is developing, in addition to LAE102, more drug candidates to maximize the value of targeting ActRII receptors. LAE103 is an ActRIIB-selective antibody and LAE123 is an ActRIIA/IIB dual antagonistic monoclonal antibody. Both are our internally discovered antibodies for muscle and other disease indications. The results of the pre-clinical study of LAE102, LAE103 (an ActRIIB selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of ADA.

The Group obtained IND approval from the U.S. FDA for LAE103 in July 2025 and has commenced the Phase I single ascending dose study (the "**LAE103 SAD Study**") of LAE103, in Australia and dosed the first subject in December 2025. The LAE103 SAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE103, administered subcutaneously, in healthy overweight or obese participants. The Group targets to read out the topline data of this SAD study in the third quarter of 2026. In addition to LAE102, the initiation of clinical study for LAE103 demonstrates our deep pipeline targeting ActRII pathway for metabolic diseases.

LAE123 is advancing through IND-enabling studies, targeting IND submission in 2026. The Group has established a comprehensive ActRII portfolio and is in discussions with potential partners for strategic cooperations to accelerate development and commercialization of our ActRII portfolio.

LAE002 (afuresertib) + Fulvestrant in HR+/HER2- breast cancer, Phase III

The Group commenced the Phase III clinical trial AFFIRM-205 in China for LAE002 (afuresertib, an oral AKT inhibitor) plus fulvestrant in patients with PIK3CA/AKT1/PTEN alterations and HR+/HER2-locally advanced or metastatic breast cancer ("**LA/mBC**") (the "**Phase III Clinical Trial AFFIRM-205**") in May 2024. The Phase III Clinical Trial AFFIRM-205 is a multi-center, randomized, double-blind, placebo-controlled pivotal study to further assess the anti-tumor efficacy and safety of the combination therapy. Study recruitment was completed in December 2025. The Group targets to readout the topline data of this phase III pivotal study in the first half of 2026, followed by submission of the new drug application to the center for drug evaluation of China's National Medical Products Administration later in the year.

In February 2026, an article titled "**Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial**" was published in ***Nature Communications***, a leading international scientific journal. The article primarily reports the results of this Phase Ib clinical trial, which evaluated afuresertib in combination with fulvestrant for the treatment of pretreated HR-positive/HER2-negative advanced breast cancer. The findings indicate that this combination regimen demonstrates promising anti-tumor activity and a well-tolerated safety profile in this patient population.

During the Reporting Period, the Group and Qilu Pharmaceutical Company Limited ("**Qilu Pharma**") have entered into an exclusive licensing agreement (the "**License Agreement**"). Subject to terms and conditions of the License Agreement, Qilu Pharma is granted an exclusive license for research, development, and commercialization of LAE002 (afuresertib) in the China region (including Chinese Mainland, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan) (the "**Licensed Territory**"). The Group is responsible for completing the ongoing HR+/HER2- breast cancer Phase III clinical trial (AFFIRM-205). In return, the Group is entitled to receive non-refundable upfront and clinical development milestone payments up to RMB530 million upon new drug application ("**NDA**") approval for the first indication in China. Under the License Agreement, the Group is eligible to receive up to RMB2,045 million in total in upfront and milestone payments and is also entitled to receive tiered royalties on future net sales of LAE002 (afuresertib) in the Licensed Territory, at percentages ranging from the low teens to the low twenties. The Group can leverage this opportunity to accelerate the regulatory approval and commercialization of LAE002 (afuresertib) in the Licensed Territory and maximize its commercial value.

LAE002 (afuresertib) +LAE001/prednisone in mCRPC, Phase II

We completed a Phase II multi-region clinical trial of the study of LAE002 (afuresertib, an AKT inhibitor) plus LAE001 (CYP17A1/CYP11B2 dual inhibitor) ("**LAE201**") in 40 patients with metastatic castration-resistant prostate cancer ("**mCRPC**") following standard of care ("**SOC**") treatment in 2024. The trial is an open-label, dose-escalation and dose expansion study to assess the efficacy and safety of the combination candidate. The study demonstrated promising treatment benefit for mCRPC patients. The median rPFS was 8.1 months. This is a significant improvement compared to the median rPFS of 2 to 4 months of mCRPC patients under the standard treatments historically. The combination therapy was generally tolerable with manageable treatment emergent adverse events and recoverable after routine treatments.

Design of the Phase III pivotal trial of LAE201 in patients with mCRPC following SOC treatment has been discussed with FDA. In May 2024, the Group obtained approval from FDA for the protocol of this Phase III clinical trial. We plan to pursue strategic partnerships to accelerate the global development and commercialization of LAE002 (afuresertib) and LAE001 to address the great unmet medical need of the cancer therapeutic area.

Pre-clinical candidates (PCC)

LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) is advancing through IND-enabling studies, targeting IND submission in 2026.

The Group also plans to complete PCC declaration for LAE124, a small molecule dual amylin and calcitonin receptor agonist (DACRA) in 2026.

In February 2026, the Group has obtained IND approval from the U.S. FDA for LAE118, a novel PI3Kα pan-mutant selective inhibitor for the treatment of patients with PIK3CA-mutant solid tumors. In April 2025, the Group presented a poster at the 2025 Annual Meeting of the American Association for Cancer Research (AACR), showcasing this internally discovered pre-clinical drug candidate for cancer. Building on its proven track record in successfully developing and out-licensing LAE002 (afuresertib), the Company aims to bring this precision therapy to cancer patients who are in need of novel treatment options.

The Group also obtained IND approval from the U.S. FDA for LAE120, an USP1 inhibitor, in February 2025.

Expected Upcoming Milestones in 2026

About LAE102

- Report results from the Phase I MAD Expansion Study in China.
- Initiate a Phase II clinical study in combination with a GLP-1 receptor agonist.

About AFFIRM-205

- Report results from the Phase III China trial (AFFIRM-205).
- Submit NDA to CDE.

About Other Metabolic Disease Drug Candidates

- Report results from Phase I SAD of LAE103.
- IND submission for LAE123.
- Complete PCC declaration for LAE124, a small molecule dual amylin and calcitonin receptor agonist (DACRA).

FINANCIAL HIGHLIGHTS

	Year ended December 31,	
	2025	2024
	RMB'000	*RMB'000*
Revenue	**106,719**	–
Gross profit	**86,419**	–
Research and development expenses	**249,901**	215,115
Loss for the year	**229,318**	254,296
Total comprehensive loss for the year	**253,706**	242,949

Our revenue amounted to RMB106.7 million in 2025, which derived from the out-licensing transaction of LAE002 (afuresertib) with Qilu Pharma.

Our research and development expenses increased by RMB34.8 million or 16.2% from RMB215.1 million in 2024 to RMB249.9 million in 2025. Such increase was primarily attributable to increased expenses related to ActRII portfolio, including LAE102, LAE103 and LAE123, and the increase in equity settled share-based payment expenses.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the year ended December 31, 2025
(Expressed in Renminbi)

	Note	**2025** ***RMB'000***	2024 *RMB'000*
Revenue	*4*	**106,719**	–
Cost of sales		**(20,300)**	–
Gross profit		**86,419**	–
Other income	*5*	**44,857**	38,169
Other losses		**(341)**	(268)
Administrative expenses		**(106,478)**	(74,058)
Research and development expenses		**(249,901)**	(215,115)
Loss from operations		**(225,444)**	(251,272)
Finance costs	*6(a)*	**(3,874)**	(3,024)
Loss before taxation	*6*	**(229,318)**	(254,296)
Income tax	*7*	**–**	–
Loss for the year		**(229,318)**	(254,296)
Other comprehensive income for the year (after tax and reclassification adjustments)			
Items that will not be reclassified to profit or loss:			
Exchange differences on translation of financial statements of the Company		**(55,628)**	28,683
Items that are or may be reclassified subsequently to profit or loss:			
Exchange differences on translation of financial statements of foreign subsidiaries		**31,240**	(17,336)
Total comprehensive income for the year		**(253,706)**	(242,949)
Loss per share			
Basic and diluted *(RMB)*	*8*	**(0.59)**	(0.71)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As of December 31, 2025
(Expressed in Renminbi)

	Note	**2025** ***RMB'000***	2024 *RMB'000*
Non-current assets			
Property, plant and equipment		**1,781**	2,686
Intangible assets	*9*	**121,134**	125,108
Right-of-use assets		**3,038**	4,774
Pledged deposits		**4,053**	–
Other non-current assets		**12,250**	14,068
		142,256	146,636
Current assets			
Prepayments and other receivables		**10,197**	13,368
Time deposits	*10*	**19,155**	163,611
Cash and bank balances	*11*	**1,243,218**	636,422
		1,272,570	813,401
Current liabilities			
Bank loans	*12*	**117,408**	99,010
Other payables	*13*	**75,338**	47,418
Contract liabilities		**34,791**	–
Lease liabilities		**2,045**	2,045
		229,582	148,473
Net current assets		**1,042,988**	664,928
Total assets less current liabilities		**1,185,244**	811,564
Non-current liabilities			
Lease liabilities		**1,387**	3,272
Deferred income		**3,500**	3,500
		4,887	6,772
NET ASSETS		**1,180,357**	804,792
CAPITAL AND RESERVES			
Share capital		**31**	28
Treasury shares		**(2)**	(2)
Reserves		**1,180,328**	804,766
TOTAL EQUITY		**1,180,357**	804,792

CONSOLIDATED CASH FLOW STATEMENT

For the year ended December 31, 2025
(Expressed in Renminbi)

	Note	**2025** ***RMB'000***	2024 *RMB'000*
Operating activities			
Cash used in operations		**(92,822)**	(278,303)
Net cash used in operating activities		**(92,822)**	(278,303)
Investing activities			
Payment for purchase of property, plant and equipment		**(174)**	(164)
Proceeds from disposal of property, plant and equipment		**14**	4
Payment for purchase of intangible assets		**(887)**	(1,749)
Payment for pledged deposit		**(4,000)**	–
Decrease in time deposits with original maturity over three months		**142,085**	176,962
Interest received from bank deposits		**34,604**	33,139
Net cash generated from investing activities		**171,642**	208,192
Financing activities			
Proceeds from bank loans		**137,420**	99,010
Repayment of bank loans		**(119,022)**	(49,400)
Interest paid for bank loans		**(3,668)**	(2,732)
Proceeds from issuance of ordinary shares by placing, net of issuance costs		**527,834**	213,159
Proceeds from exercise of share options		**6,007**	–
Payment for capital element of lease liabilities		**(1,885)**	(1,669)
Payment for interest element of lease liabilities		**(206)**	(292)
Net cash generated from financing activities		**546,480**	258,076
Net increase in cash and cash equivalents		**625,300**	187,965
Cash and cash equivalents at January 1	*11*	**634,323**	440,815
Effect of foreign exchange rate changes		**(18,855)**	5,543
Cash and cash equivalents at December 31	*11*	**1,240,768**	634,323

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1 GENERAL INFORMATION

The Company was incorporated in the Cayman Islands on July 29, 2016 as an exempted company with limited liability under the law of the Cayman Islands.

The Company is an investing holding company. The Group is principally engaged in discovering, developing and commercialising innovative therapies to patients with metabolic diseases, cancer and liver fibrosis around the world.

The Company's shares were listed on the Main Board of The Stock Exchange on June 29, 2023.

2 BASIS OF PREPARATION

The consolidated financial statements for the year ended December 31, 2025 comprise the Company and its subsidiaries.

The consolidated financial statements have been prepared in accordance with IFRS Accounting Standards using the historical cost basis.

The financial information relating to the financial year ended December 31, 2025 that is included in this preliminary annual results announcement does not constitute the Group's annual consolidated financial statements for that financial year but is derived from those financial statements.

3 CHANGES IN ACCOUNTING POLICIES

The Group has applied amendments to IAS 21, *The effects of changes in foreign exchange rates — Lack of exchangeability* issued by the IASB to these financial statements for the current accounting period. The amendments do not have a material impact on these financial statements as the Group has not entered into any foreign currency transactions in which the foreign currency is not exchangeable into another currency.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

4 REVENUE AND SEGMENT REPORTING

(a) Revenue

The principal activities of the Group are the discovering, developing and commercialising innovative therapies to patients with metabolic diseases, cancer and liver fibrosis. During the year ended December 31, 2025, the Group's revenue was derived from license agreement by granting licenses of certain intellectual properties to Qilu Pharma and providing research and development services in relation to the licensed products to the customer.

(i) Disaggregation of revenue

Disaggregation of revenue from contracts with customers by major products or service lines is as follows:

	Year ended December 31,	
	2025	2024
	RMB'000	*RMB'000*
Revenue from contracts with customers within the scope of IFRS 15		
Revenue from the license	**88,702**	–
Revenue from provision of research and development services	**18,017**	–
	106,719	–
Disaggregated by timing of revenue recognition		
— Point in time	**88,702**	–
— Over time	**18,017**	–
	106,719	–

Revenue from each major customer which accounted for 10% or more the Group's revenue is set out below:

	Year ended December 31,	
	2025	2024
	RMB'000	*RMB'000*
Qilu Pharma	**106,719**	–

(ii) Revenue expected to be recognised in the future arising from contracts with customers in existence at the reporting date.

As at December 31, 2025, the aggregated amount of the transaction price allocated to the remaining performance obligations under the Group's existing contracts is RMB34,791,000 (2024: nil), which is expected to occur over the next 12 months.

The above amount does not include any amounts of milestone payments that the Group may earn in the future by meeting the conditions set out in the Group existing contracts with customers, unless at the reporting date it is highly probable that the Group will satisfy the conditions for earning those payments.

(b) Segment and geographical information

For the purpose of making decisions about resources allocation and performance assessment, the Group's management focuses on the operating results of the Group as a whole. As such, the Group's resources are integrated, and no discrete operating segment information is available. Accordingly, no operating segment information is presented.

Since all of the Group's revenue and operating profit were generated from the sales in Chinese Mainland and most of the Group's identifiable operating assets were located in Chinese Mainland, no geographical segment information in accordance with IFRS 8 Operating Segments is presented.

During the year ended December 31, 2025, the Group generated total revenue of RMB106,719,000, exclusively in Chinese Mainland.

5 OTHER INCOME

	Year ended December 31,	
	2025	2024
	RMB'000	*RMB'000*
Interest income from bank deposits	**32,636**	37,645
Government grants	**6,078**	524
Net foreign exchange gains	**3,133**	–
Others	**3,010**	–
	44,857	38,169

6 LOSS BEFORE TAXATION

Loss before taxation is arrived at after charging/(crediting):

(a) Finance costs

	Year ended December 31,	
	2025	2024
	RMB'000	*RMB'000*
Interest on bank loans	**3,668**	2,732
Interest on lease liabilities	**206**	292
	3,874	3,024

(b) Staff costs

	Year ended December 31,	
	2025	2024
	RMB'000	*RMB'000*
Salaries, wages and other benefits	**87,984**	99,248
Contributions to defined contribution retirement plan (i)	**5,125**	5,167
Equity settled share-based payment expenses	**95,733**	30,307
	188,842	134,722

(c) Other items

	Year ended December 31,	
	2025	2024
	RMB'000	*RMB'000*
Amortisation of intangible assets	**2,694**	2,127
Depreciation charge		
— property, plant and equipment	**1,020**	1,286
— right-of-use assets	**1,736**	1,736
	2,756	3,022
Auditors' remuneration		
— audit services	**3,000**	3,000
— tax services	**35**	32
	3,035	3,032
Research and development expenses (ii)	**249,901**	215,115
Cost of sales (iii)	**20,300**	–

(i) The full-time employees of the Group are entitled to various government-sponsored defined-contribution retirement plans. The Group contributes on a monthly basis to these funds based on certain percentages of the salaries of the employees, subject to certain ceiling. The Group's liability in respect of these funds is limited to the contributions payable in each year.

(ii) During the year ended December 31, 2025, research and development expenses included staff costs, depreciation and amortisation expenses of RMB101,014,000 in total (2024: RMB83,459,000), in which the respective amounts were also disclosed separately above.

(iii) During the year ended December 31, 2025, cost of sales included staff costs, depreciation and amortisation expenses of RMB3,429,000 in total (2024: nil), in which the respective amounts were also disclosed separately above.

7 INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

(i) The Cayman Islands

Pursuant to the rules and regulations of the Cayman Islands, the Company is currently not subject to income tax.

(ii) Hong Kong, China

The Company's subsidiary incorporated in Hong Kong is subject to Hong Kong profits tax at 16.5% of the estimated assessable profits. No provision for Hong Kong profits tax had been made for the years ended December 31, 2025 and 2024 as there were no assessable profits.

(iii) The U.S.

The Company's subsidiary incorporated in the USA is subject to Federal Tax at a rate of 21% and State Profits Tax at a rate of 0.75%–9.00% (2024: 0.75%–9.50%). Operations in the USA have incurred net accumulated operating losses for income tax purposes, and no income tax provisions had been made for the years ended December 31, 2025 and 2024.

(iv) Chinese Mainland

No provision for Chinese Mainland income tax pursuant to the Corporate Income Tax Law of the People's Republic of China and the respective regulations has been made as the Group's subsidiaries which operate in Chinese Mainland are in loss position and have no estimated taxable profits.

Pursuant to the Corporate Income Tax Law of Chinese Mainland (the "**CIT**"), the Company's Chinese Mainland subsidiaries are subject to the CIT at a rate of 25%.

According to the new tax incentive policies promulgated by the State Tax Bureau of Chinese Mainland in March 2023, effective from January 1, 2023, an additional 100% of qualified research and development expenses incurred is allowed to be deducted from taxable income.

8 LOSS PER SHARE

The calculation of basic loss per share is based on the loss attributable to ordinary equity shareholders of the Company of RMB229,318,000 (2024: RMB254,296,000) and the weighted average of 388,983,000 ordinary shares (2024: 357,626,000 shares) in issue during the year.

The calculation of diluted loss per share for the years ended December 31, 2025 and 2024 has not included the potential effects of share options and restricted share units issued by the Company, as their inclusion would be anti-dilutive. Accordingly, diluted loss per share for the years ended December 31, 2025 and 2024 are the same as basic loss per share.

9 INTANGIBLE ASSETS

	In-licensed rights *RMB'000*	Software *RMB'000*	Total *RMB'000*
Cost:			
At January 1, 2024	120,711	6,602	127,313
Additions	–	322	322
Transfers	–	883	883
Exchange adjustments	1,801	–	1,801
At December 31, 2024 and January 1, 2025	122,512	7,807	130,319
Additions	–	1,411	1,411
Transfers	–	(273)	(273)
Exchange adjustments	(2,418)	–	(2,418)
At December 31, 2025	120,094	8,945	129,039
Accumulated amortisation:			
At January 1, 2024	–	(3,084)	(3,084)
Charge for the year	–	(2,127)	(2,127)
At December 31, 2024 and January 1, 2025	–	(5,211)	(5,211)
Charge for the year	(618)	(2,076)	(2,694)
At December 31, 2025	(618)	(7,287)	(7,905)
Net book value:			
At December 31, 2025	**119,476**	**1,658**	**121,134**
At December 31, 2024	**122,512**	**2,596**	**125,108**

In-licensed rights

The balance of in-licensed rights represents payments made to acquire development and commercialisation rights of drug products from third parties. Due to the inherent uncertainties in the research and development processes, these assets are particularly at risk of impairment if the projects are not expected to result in commercialised products. Key terms of these licenses are set out below:

(i) LAE001

On June 30, 2017, the Group entered into a license agreement with Novartis Pharma AG ("**Novartis**"), pursuant to which Novartis granted the Group an exclusive license to develop, manufacture and commercialise the licensed product LAE001 world widely.

Under the terms of the agreement, the Group made an one-time and non-refundable upfront payment of USD1 million (equivalent to RMB6.6 million) and granted 776,437 ordinary shares of the Company to Novartis (equaling to 7,764,370 shares after adjusting for the effect of the share subdivision upon the Listing). The Group capitalised an amount of USD1.8 million (equivalent to RMB12.2 million) in total. The Group also agreed to make regulatory milestone payments, as well as royalty payments on net sales to Novartis. As at December 31, 2025, LAE001 was not ready for commercial use.

(ii) LAE002 (afuresertib) & LAE003

On May 9, 2018, the Group entered into a license agreement with Novartis, pursuant to which Novartis granted the Group an exclusive license to develop, manufacture and commercialise the licensed products LAE002 (afuresertib) and LAE003 world widely.

Under the terms of the agreement, the Group made an one-time and non-refundable upfront payment of USD5 million (equivalent to RMB31.9 million) and granted 165,200 ordinary shares of the Company to Novartis (equaling to 1,652,000 shares after adjusting for the effect of the share subdivision upon the Listing). The Group capitalised an amount of USD5.2 million (equivalent to RMB33.5 million) in total. The Group also agreed to make clinical trial milestone payments, regulatory milestone payments, sales milestone payments, as well as royalty payments on net sales to Novartis.

In 2025, the Group entered into an exclusive license agreement with Qilu Pharma for research, development, and commercialisation of LAE002 (afuresertib) in China. Accordingly, the products started commercial use and relevant in-licensed rights commenced amortisation in 2025.

(iii) LAE005

On February 4, 2020, the Group entered into a license agreement with Novartis, pursuant to which Novartis granted the Group an exclusive license to develop, manufacture and commercialise the products LAE005 world widely.

Under the terms of the agreement, the Group made an one-time and non-refundable upfront payment of USD10 million (equivalent to RMB69.4 million) to Novartis and capitalised such payment. The Group also agreed to make clinical trial milestone payments, regulatory milestone payments, sales milestone payments, as well as royalty payments on net sales to Novartis. As at December 31, 2025, LAE005 was not ready for commercial use.

(iv) Impairment test

Intangible assets not yet ready for commercial use are tested annually based on the recoverable amount of the CGU to which the intangible asset is related. The appropriate CGU is at the product level. The annual impairment test was performed for each drug by engaging an independent qualified professional valuer to estimate fair value less costs of disposal as the recoverable amount of each drug. The fair value is based on the multi-period excessive earning method and the Group estimated the forecast period till year 2035 for each drug based on the timing of clinical development and regulatory approval, commercial ramp up to reach expected peak revenue potential, and the length of exclusivity for each product. The estimated revenue of each drug is based on management's expectations of timing of commercialization. The costs and operating expenses are estimated as a percentage over the revenue forecast period based on the current margin levels of comparable companies with adjustments made to reflect the expected future price changes. The discount rates used are post-tax and reflect the general business and market risk of the Group. The discount rates are derived from capital asset pricing model by taking applicable market data into account, such as risk-free rate, market premium, beta, company specific risk and size premium, etc.

The key assumptions used in estimating the recoverable amount are as follows:

	2025	2024
LAE001		
Discount rate	**17%**	17%
Revenue growth rate	**10% to 37%**	–3% to 77%
Recoverable amount of CGU *(in RMB million)*	**54.3**	203.3
LAE005		
Discount rate	**17%**	17%
Revenue growth rate	**0% to 76%**	–6% to 17%
Recoverable amount of CGU *(in RMB million)*	**101.5**	113.8

Based on the result of the above assessment, there were no impairment for the in-licensed rights as at December 31, 2025 and 2024.

10 TIME DEPOSITS

	2025	2024
	RMB'000	*RMB'000*
Bank deposits with original maturity over three months	**19,073**	161,158
Accrued interest	**82**	2,453
	19,155	163,611

11 CASH AND BANK BALANCES

	2025	2024
	RMB'000	*RMB'000*
Cash at banks	**113,785**	194,172
Deposits with banks	**1,126,983**	440,151
Cash and cash equivalents in the consolidated cash flow statement	**1,240,768**	634,323
Accrued interest	**2,450**	2,099
Cash and bank balances in the consolidated statement of financial position	**1,243,218**	636,422

As at December 31, 2025, cash and cash equivalents of the Group situated in Chinese Mainland amounted to RMB404,400,000 (2024: RMB259,738,000). Remittance of funds out of Chinese Mainland is subject to relevant rules and regulations of foreign exchange control.

12 BANK LOANS

	2025	2024
	RMB'000	*RMB'000*
Unsecured bank loans due within 1 year	**117,408**	99,010

As at December 31, 2025, unsecured bank loans carried interest at annual rates ranging from 2.37% to 3.85% (2024: 3.20% to 4.10%) per annum and were all repayable within one year.

13 OTHER PAYABLES

	2025	2024
	RMB'000	*RMB'000*
Payroll payables	**12,744**	13,456
Accrued research and development expenses	**54,937**	29,048
Other payables and accrued charges	**7,657**	4,914
	75,338	47,418

14 DIVIDENDS

The directors of the Company did not propose any payment of dividend for the year ended December 31, 2025 (2024: nil).

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

We are a science-driven, clinical-stage biotechnology company committed to bringing novel therapeutics to patients with metabolic diseases, cancer and liver fibrosis around the world. We have assembled a seasoned management team with extensive experience and expertise covering the full cycle of drug discovery and development process, from pre-clinical asset discovery, clinical trial design and execution to regulatory process management and drug manufacturing. As of December 31, 2025, we were supported by a talented R&D team consisting of 59 employees, with 11 holding doctorate degrees and 30 holding master's degrees. Our core management team has established a long track record of accomplishment, leadership and deep knowledge in their respective fields.

We focus on specific fields where we have accumulated tremendous experience and extensive know-how. As of December 31, 2025, we have initiated seven clinical trials for LAE102, LAE103, LAE002 (afuresertib), LAE001 and LAE005 to address unmet medical needs in obesity and cancers.

Globally, the number of people living with obesity is set to reach over 1.1 billion by 2030[1]. The causes of obesity are complex and, so often, it puts people on a path to other diseases — not only diabetes, but also heart and liver diseases, cancers and many more. There are growing understandings of the critical need to treat obesity among both the medical community and the public, while an increasing number of people living with such disease are actively seeking support.

In the field of cancer, we have observed notable progress in treatment over the past decade. However, a significant proportion of cancer patients still find themselves in the absence of effective or safe treatments. The quality of life of those patients is severely affected, primarily attributable to SOC treatment resistance and/or intolerable toxicity, resulting in a large unmet medical need and a socioeconomic burden. Among those cancers of unmet medical need, HR+/HER2- metastatic breast cancer (HR+/HER2- mBC), mCRPC, PROC and triple negative breast cancer (TNBC) are some of the diseases with limited SOC options and unsatisfactory treatment outcomes.

We are committed to advancing and expanding our product portfolio in therapeutic areas where we have accumulated deep expertise and extensive know-how and to delivering life-changing therapies to address unmet medical needs.

[1] World Obesity Atlas, 2025

PIPELINE

The following chart summarizes the development status of our clinical and pre-clinical stage drug candidates as of the date of this announcement:



BUSINESS REVIEW

During the year ended December 31, 2025, the Company achieved significant progress across its drug candidate pipeline and business operations, including the following milestones and achievements.

LAE102 in Obesity, Phase I

LAE102 is our internally discovered monoclonal antibody against ActRIIA. Blocking Activin-ActRII pathway could promote muscle regeneration and reduce fat mass, positioning LAE102 as a promising drug candidate for muscle-preserving weight control.

In January 2025, the Group announced positive results from the SAD Study of LAE102 for the treatment of obesity. The study enrolled 40 participants in Part A (IV) and 24 participants in Part B (SC). All participants were healthy volunteers and completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m^2 and 23.08 kg/m^2 in Part A and Part B, respectively. Baseline demographic and clinical characteristics were generally balanced across the IV and SC cohorts of the study. Overall, LAE102 was well tolerated following a single IV or SC dose. No serious adverse events or TEAEs leading to discontinuation of treatment were

reported. The majority of the TEAEs were mild laboratory test abnormalities, which were asymptomatic and did not require medical intervention. There was no reported case of diarrhea. Activin A levels increased rapidly within 24 hours following a single intravenous or subcutaneous dose of LAE102, with the duration of elevated Activin A levels shown to be dose-dependent. In the high-dose groups, 2-to-3-fold increases above baseline were maintained through 28 days post-administration, indicating prolonged pathway blockade. The robust PK/PD correlation supports potential efficacy and provides a strong rationale for further clinical development of LAE102 in overweight and obese populations, thereby establishing a solid foundation for the MAD Study. Detailed study results were presented at the 85th Scientific Sessions of the ADA in June 2025.

The Group had commenced subject recruitment for the Phase I MAD Study of LAE102 by the end of March 2025. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in overweight/obese subjects. The MAD Study enrolled overweight/obese subjects with an average BMI of 29.4 kg/m^2, including 3 subcutaneous ascending dose cohorts, given weekly for 5 doses). The preliminary results demonstrated encouraging trends toward increased lean body mass and reduced fat mass. At week 5, the LAE102 6 mg/kg group exhibited a 1.7% increase in mean lean body mass and a 2.2% reduction in mean fat mass compared to the baseline. Adjusted from the placebo control group, the mean lean body mass is increased by 4.6%, whereas the mean fat mass is reduced by 3.6%. Consistent with the prior Phase I SAD Study of LAE102, the MAD Study demonstrated a well-tolerated safety profile, with no serious adverse events reported. Majority of TEAEs were mild (grade 1) and transient laboratory test abnormality. No cases of diarrhea, muscle spasm or acne were observed. The safety profile was consistent with prior data and no new safety signals emerged. LAE102 serum concentration reached steady state after 5 weekly subcutaneous injections and the PK profile was consistent with that observed in the SAD Study. The robust PK/PD correlation further demonstrates the potential efficacy of LAE102 in overweight and obese populations.

Following the positive one-month results observed in the early MAD study, the pre-planned Multiple Dose Expansion Study was initiated to further evaluate the efficacy and safety profile of LAE102 over a longer treatment duration. In December 2025, the Group commenced subject recruitment for this study and dosed the first participant. The Phase I Multiple Dose Expansion Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102, administered subcutaneously, in overweight/obese subjects. A total of 60 participants were enrolled and randomized to receive either LAE102 or placebo for a 6-month treatment period.

In March 2026, the Group announced successful completion, in collaboration with Eli Lilly and Company, of the Phase I single ascending dose study (the "**U.S. SAD Study**") of LAE102 in the U.S. Consistent with the prior safety profile of LAE102, the U.S. SAD Study demonstrated a well-tolerated safety profile, with no serious adverse events reported. The U.S. SAD Study showed encouraging trends in body composition improvements following administration of a single dose. Dose-dependent effects on lean body mass increase and fat mass reduction were observed. On Day 29 following a single dose of LAE102, the group with the highest exposure exhibited a 5.06% increase in mean lean body mass from baseline (placebo group has 1.34% reduction from baseline) and a 0.12% decrease in mean fat mass from baseline (placebo group has 2.11% increase from baseline). These positive results added to a growing body of data supporting LAE102 as a therapeutic approach to obesity.

Laekna team has accumulated tremendous experience and extensive know-how in this field and, in addition to LAE102, is developing additional drug candidates to maximize the therapeutic potential of targeting ActRII receptors. LAE103 is an ActRIIB-selective antibody and LAE123 is an ActRIIA/IIB dual antagonistic monoclonal antibody. Both are our internally discovered antibodies for muscle and other disease indications.

The results of the pre-clinical studies of LAE102, LAE103 (an ActRIIB selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th Scientific Sessions of ADA in June 2025. LAE102, LAE103, and LAE123 are high-affinity functional antagonists that completely inhibit signaling transduced by ligands such as activin A, B, AB, and MSTN, all of which are known to contribute to muscle atrophy. In addition, they inhibit activin E and GDF3, which promote lipid accumulation in adipose tissue. In mouse models, LAE102 alone significantly induced muscle growth and reduced fat mass. Notably, a synergistic effect on muscle increase and fat loss was observed when LAE102 was combined with LAE103, achieving maximal efficacy comparable to the ActRIIA/IIB dual antagonistic monoclonal antibody LAE123. These findings indicate that ActRIIA is a major regulator of muscle growth and fat loss in mice. LAE102 demonstrates strong potential as a muscle-preserving weight management therapy with a favorable safety profile, while LAE123 could be utilized in the treatment of severe diseases requiring complete inhibition of both ActRIIA and ActRIIB.

The Group obtained IND approval from the U.S. FDA for LAE103 in July 2025 and subsequently initiated the Phase I SAD Study of LAE103 in Australia, dosing the first subject in December 2025. The LAE103 SAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE103, administered subcutaneously, in healthy overweight or obese participants. The Group targets to read out the topline data of this SAD study in the third quarter of 2026.

LAE123 is progressing through IND-enabling studies, with IND submission targeted for 2026. The Group has established a comprehensive ActRII portfolio and is engaged in discussions with potential partners for strategic collaborations to accelerate development and commercialization of our ActRII portfolio.

LAE002 (afuresertib)

Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. We in-licensed Afuresertib from Novartis in 2018. Prior to our in-licensing, 11 clinical trials had been conducted to demonstrate the safety and efficacy profiles of Afuresertib by Novartis and GSK.

LAE002 (afuresertib) + Fulvestrant in HR+/HER2- breast cancer, Phase III

The Group commenced the Phase III Clinical Trial AFFIRM-205 in China for LAE002 (afuresertib, an oral AKT inhibitor) plus fulvestrant in patients with PIK3CA/AKT1/PTEN alterations and HR+/HER2-LA/mBC in May 2024. The Phase III Clinical Trial AFFIRM-205 is a multi-center, randomized, double-blind, placebo-controlled pivotal study to further assess the anti-tumor efficacy and safety of the combination therapy. Study recruitment was completed in December 2025. The Group expects the topline data readout from this Phase III pivotal study to be presented in the first half of 2026, followed by submission of the NDA to the center for drug evaluation of China's National Medical Products Administration later in the year.

In February 2026, an article titled "**Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial**" was published in ***Nature Communications***, a leading international scientific journal. The article primarily reports the results of this Phase Ib clinical trial, which evaluated afuresertib in combination with fulvestrant for the treatment of pretreated HR-positive/HER2-negative advanced breast cancer. The findings indicate that this combination regimen demonstrates promising anti-tumor activity and a well-tolerated safety profile in this patient population.

During the Reporting Period, the Group and Qilu Pharma have entered into the License Agreement. Subject to terms and conditions of the License Agreement, Qilu Pharma is granted an exclusive license for research, development, and commercialization of LAE002 (afuresertib) in the China region (including Chinese Mainland, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). The Group is responsible for completing the ongoing HR+/HER2- breast cancer Phase III clinical trial (AFFIRM-205). In return, the Group is entitled to receive non-refundable upfront and clinical development milestone payments up to RMB530 million upon NDA approval for the first indication in China. Under the License Agreement, the Group is eligible to receive up to RMB2,045 million in total in upfront and milestone payments and is also entitled to receive tiered royalties on future net sales of LAE002 (afuresertib)

in the Licensed Territory, at percentages ranging from the low teens to the low twenties. The Group can leverage this opportunity to accelerate the regulatory approval and commercialization of LAE002 (afuresertib) in the Licensed Territory and maximize its commercial value.

LAE002 (afuresertib) +LAE001/prednisone in mCRPC, Phase II

We completed a Phase II multi-region clinical trial of LAE201 in 40 patients with mCRPC following SOC treatment in 2024. The trial is an open-label, dose-escalation and dose expansion study to assess the efficacy and safety of the combination candidate. The study demonstrated promising treatment benefit for mCRPC patients. The median rPFS was 8.1 months. This is a significant improvement compared to the median rPFS of 2 to 4 months of mCRPC patients under the standard treatments historically. The combination therapy was generally tolerable with manageable treatment emergent adverse events and recoverable after routine treatments.

Design of the Phase III pivotal trial of LAE201 in patients with mCRPC following SOC treatment has been discussed with FDA. In May 2024, the Group obtained approval from FDA for the protocol of this Phase III clinical trial. We plan to pursue strategic partnerships to accelerate the development and commercialization of LAE002 (afuresertib) and LAE001 to address the great unmet medical need of the cancer therapeutic area.

LAE001

LAE001 is an androgen synthesis inhibitor that inhibits both CYP17A1 and CYP11B2. We in-licensed LAE001 from Novartis in 2017. According to Frost & Sullivan, LAE001 is the only dual CYP17A1/CYP11B2 inhibitor in clinical trials for the treatment of prostate cancer globally. As a dual CYP17A1/CYP11B2 inhibitor, LAE001 can block both androgen and aldosterone synthesis and potentially be administrated without prednisone, the short-term high dose or long-term exposure of which can lead to a variety of adverse events.

We completed a Phase I clinical trial of LAE001 as a monotherapy and a Phase II clinical trial of LAE001 plus LAE002 (afuresertib) in patients with mCRPC to assess the safety and efficacy of the therapies. Design of the Phase III pivotal trial of LAE201 in patients with mCRPC following SOC treatment has been discussed with FDA and approval of the same was obtained in May 2024. We plan to pursue strategic partnerships to accelerate the development and commercialization of LAE001 to address the unmet medical need for cancer therapies.

LAE005

LAE005 is a high-affinity, ligand-blocking, humanized anti-PD-L1 IgG4 antibody. In pre-clinical and clinical studies, LAE005 demonstrated its strong binding avidity to PD-L1 and compelling anti-tumor activities. Specifically, we are evaluating the therapeutic potential of the combination therapy of LAE002 (afuresertib) and LAE005 in patients with triple-negative breast cancer (the "**TNBC**"). We believe LAE005 has the potential to serve as an effective therapy for TNBC, particularly when combined with other synergistic mechanisms.

The results of our Phase I clinical trial of LAE002 (afuresertib) in combination with LAE005 (anti-PDL1 mAb) plus nab-paclitaxel for the treatment of TNBC were presented at the AACR in April 2024. A total of 22 subjects with advanced solid tumors were enrolled and dosed in this Phase I study, among which there were 14 TNBC subjects who completed at least 2 cycles of treatment and had at least 1 tumor assessment. The median value of previous treatment lines of these 14 subjects was 1.5 (0-3). Among them, five showed confirmed partial response (ORR 35.7%), four had stable disease (28.6%), resulting in a disease control rate (DCR) of 64.3% in the best response assessment. The median duration of response (DOR) was 9.26 months. Five TNBC subjects were treated for more than 32 weeks, with one subject reaching a duration of 73 weeks. This case study has been selected for the "Chinese Clinical Case Achievement Database" (with the PFS of this case being 16 months as of September 28, 2023). We plan to pursue strategic partnerships to accelerate the development and commercialization of LAE005, addressing the significant unmet medical need in cancer therapies.

CAUTIONARY STATEMENT: WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP OR MARKET THE RELEVANT PRODUCTS, OR ANY OF OUR PIPELINE PRODUCTS, SUCCESSFULLY.

FINANCIAL REVIEW

The following discussion is based on, and should be read in conjunction with, the financial information and notes included elsewhere in this announcement.

Revenue

Our revenue amounted to RMB106.7 million in 2025, which derived from the out-licensing transaction of LAE002 (afuresertib) pursuant to the License Agreement the Group entered into with Qilu Pharma.

Cost of sales

Our cost of sales amounted to RMB20.3 million in 2025, mainly consisted of clinical development expenses related to Phase III Clinical Trial AFFIRM-205.

Other Income

Our other income increased by RMB6.7 million or 17.5% from RMB38.2 million in 2024 to RMB44.9 million in 2025, which was primarily attributable to the increase in government grants.

Administrative Expenses

Our administrative expenses increased by RMB32.4 million or 43.7% from RMB74.1 million in 2024 to RMB106.5 million in 2025, which was primarily attributable to the increase in equity settled share-based payment expenses.

Research and Development Expenses

Our research and development expenses increased by RMB34.8 million or 16.2% from RMB215.1 million in 2024 to RMB249.9 million in 2025, which was primarily attributable to increased expenses related to ActRII portfolio, including LAE102, LAE103 and LAE123, and the increase in equity settled share-based payment expenses.

	Year ended December 31,	
	2025	2024
	RMB'000	*RMB'000*
Staff costs	**96,714**	78,679
Discovery research expenses	**57,365**	27,948
Clinical development expenses	**86,155**	78,633
Clinical trial milestone payment	**–**	17,785
Others	**9,667**	12,070
Total	**249,901**	215,115

Liquidity and Financial Resource

As of December 31, 2025, the current assets of the Group were RMB1,272.6 million, including cash and bank balances of RMB1,243.2 million, time deposits with an original maturity over three months of RMB19.2 million and other current assets of RMB10.2 million. Among them, the Group's cash and bank balances increased by RMB606.8 million or 95.3% to RMB1,243.2 million as of December 31, 2025 from RMB636.4 million as of December 31, 2024. The Group's time deposits decreased to RMB19.2 million as of December 31, 2025 from RMB163.6 million as of December 31, 2024. As of December 31, 2025, the current liabilities of the Group were RMB229.6 million, including other payables of RMB75.4 million, interest-bearing bank loans of RMB117.4 million, contract liabilities of RMB34.8 million and current lease liabilities of RMB2.0 million.

Our cash and bank balances and time deposits balances as of December 31, 2025, were RMB1,262.4 million, of which RMB109.2 million, RMB1,152.0 million and RMB1.2 million were denominated in RMB, USD, and HKD, respectively, representing an increase of 57.8% as compared to the cash and bank balances and time deposits balances of RMB800.0 million as of December 31, 2024. The increase was primarily attributable to the proceeds from the Placing in September 2025 and upfront payment received by the Group from our out-licensing transaction pursuant to the License Agreement the Group entered into with Qilu Pharma.

Funding and Treasury Policy

The Group adopts a prudent funding and treasury policy, aiming to maintain an optimal financial position and minimal financial risks. We have formulated internal control measures to control our process of investment in wealth management products. Prior to making an investment, we ensure that there remains sufficient working capital for our operations, R&D activities and capital expenditures. In 2025, we funded our operations primarily through equity financing, upfront payment from our out-licensing transaction and bank loans. With the continuing expansion of our business and development of new drug candidates, we will use the net proceeds raised from the Global Offering and the placing in November 2024 and September 2025, and may require further funding through public or private equity offerings, debt financing and other sources.

Bank Loans

Our bank loans as of December 31, 2025 were RMB117.4 million (December 31, 2024: RMB99.0 million), all of which were denominated in RMB and carried fixed nominal interest rates ranging from 2.37% to 3.85% per annum.

Current ratio

Current ratio (calculated by current assets divided by current liabilities) of the Group as of December 31, 2025, was 5.54 (December 31, 2024: 5.48).

Gearing ratio

Gearing ratio is calculated by using interest-bearing borrowings and lease liabilities less cash and cash equivalents, divided by total equity and multiplied by 100%. As of December 31, 2025, the Group was in a net cash position and thus, gearing ratio is not applicable.

Foreign Currency Risk

We have transactional currency exposures. Certain of our cash and bank balances, time deposits, prepayments, other receivables and other payables are denominated in non-functional currencies and exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

Contingent Liabilities

As of December 31, 2025, we did not have any material contingent liabilities.

Significant Investments Held

As of December 31, 2025, the Group did not hold any significant investments. Save as disclosed in this announcement, as of December 31, 2025, the Group did not have future plans for material investments and investment in capital assets.

Pledge of Assets

As at December 31, 2025, deposits of RMB4.1 million were pledged to secure issuance of a bank letter of guarantee.

Employees and Remuneration Policies

As of December 31, 2025, the Group had 83 employees. The total employee benefit expenses for 2025, including share-based payment expenses, were RMB188.8 million, as compared to RMB134.7 million for 2024. Such increase was primarily attributable to the increase in equity settled share-based payment expenses.

Our employees' remuneration comprises salaries, bonuses, provident funds, social security contributions and other welfare payments. We have made contributions to our employees' social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds pursuant to applicable laws and regulations.

We adopted the Post-IPO Share Option Scheme on June 9, 2023, which was immediately prior to Listing. We further adopted the 2024 Share Award Scheme on June 14, 2024. Each of the schemes constitutes a share scheme governed by Chapter 17 of the Listing Rules.

Material Acquisitions and Disposals

During the Reporting Period, the Group did not have any material acquisition or disposal of its subsidiaries, associates and joint ventures.

Use of Net Proceeds from the Global Offering

On June 29, 2023, 63,728,000 shares of US$0.00001 each were issued at a price of HK$12.41 per share in connection with the Company's listing on the Main Board of the Stock Exchange. The net proceeds of HK$724.4 million from the Global Offering were utilised during the Reporting Period, and the unutilized net proceeds are intended to be used, in accordance with the intended use of proceeds as previously set out in the Prospectus.

The below table sets out the proposed and actual applications of the net proceeds from the Listing Date to December 31, 2025:

Intended use of Net Proceeds	Net Proceeds from the Global Offering *(HK$ million)*	Approximate % of total Net Proceeds	Unutilized Net Proceeds from the Global Offering as of January 1, 2025 *(HK$ million)*	Utilized Net Proceeds from the Global Offering during the year ended December 31, 2025 *(HK$ million)*	Utilized Net Proceeds from the Global Offering as of December 31, 2025 *(HK$ million)*	Unutilized Net Proceeds from the Global Offering as of December 31, 2025 *(HK$ million)*	Expected timeline of full utilization of the unutilized Net Proceeds[(1)]
For rapidly advancing the clinical development and approval of our Core Products, i.e. LAE001 and LAE002 (afuresertib)	407.8	56.3%	181.0	87.7	314.5	93.3	Before December 31, 2026
For accelerating the research and development of other existing pipeline products and continuously advancing and improving our pipeline products	150.7	20.8%	35.6	35.6	150.7	–	
For improving our production capabilities and developing our manufacturing capacities	71.7	9.9%	66.8	–	4.9	66.8	Before December 31, 2027
For business development activities and enhancing our global reach	55.1	7.6%	34.7	15.4	35.8	19.3	Before December 31, 2026
For working capital and other general corporate purposes	39.1	5.4%	–	–	39.1	–	

Note:

(1) The expected timeline is based on the best estimation made by the Group on future market condition and may change with the future market condition and future development.

Use of Net Proceeds from the Placing in November 2024

On November 27, 2024, the Company completed a placing of an aggregate of 17,636,000 placing shares to not less than six placees at a price of HK$13.36 per placing share pursuant to the terms and conditions of the placing agreement dated November 21, 2024. The gross proceeds from the placing were approximately HK$235.6 million. The Company received net proceeds from the placing, after deducting the placing commission and other related expenses and professional fees, of approximately HK$230.4 million. The net proceeds from the placing were utilised during the Reporting Period, and the unutilized net proceeds are intended to be used, in accordance with the intended use of proceeds as previously set out in the announcement of the Company dated November 21, 2024.

The below table sets out the proposed and actual applications of the net proceeds during the Reporting Period:

Intended Use of Net Proceeds	Net Proceeds from the Placing *(HK$ million)*	Approximate % of Total Net Proceeds	Unutilized Net Proceeds from the Placing as of January 1, 2025 *(HK$ million)*	Utilized Net Proceeds from the Placing during the year ended December 31, 2025 *(HK$ million)*	Utilized Net Proceeds from the Placing as of December 31, 2025 *(HK$ million)*	Unutilized Net Proceeds from the Placing as of December 31, 2025 *(HK$ million)*	Expected Timeline of Full Utilization of the Unutilized Net Proceeds[(1)]
For accelerating research and development of LAE102 and other drug assets targeting ActRII receptors	230.4	100.0%	228.3	95.2	97.3	133.1	Before December 31, 2026

Note:

(1) The expected timeline is based on the best estimation made by the Group on future market condition and may change with the future market condition and future development.

Use of Net Proceeds from the Placing in September 2025

On September 17, 2025, the Company completed a placing of an aggregate of 36,000,000 placing shares to not less than six placees at a price of HK$16.30 per placing share pursuant to the terms and conditions of the Placing Agreement. The gross proceeds from the Placing were approximately HK$586.8 million. The Company received net proceeds from the Placing, after deducting the placing commission and other related expenses and professional fees, of approximately HK$577.5 million. The net proceeds from the Placing were utilised during the Reporting Period, and the unutilized net proceeds are intended to be used, in accordance with the intended use of proceeds as previously set out in the announcement of the Company dated September 10, 2025.

The below table sets out the proposed and actual applications of the net proceeds during the Reporting Period:

Intended Use of Net Proceeds	Net Proceeds from the Placing *(HK$ million)*	Approximate % of Total Net Proceeds	Utilized Net Proceeds from the Placing as of December 31, 2025 *(HK$ million)*	Unutilized Net Proceeds from the Placing as of December 31, 2025 *(HK$ million)*	Expected Timeline of Full Utilization of the Unutilized Net Proceeds[(1)]
R&D expenses on ActRII portfolio, including LAE102, LAE103 and LAE123	349.8	60.6%	–	349.8	Before December 31, 2027
Ongoing R&D expenses on preclinical drug candidates	170.0	29.4%	15.7	154.3	Before December 31, 2027
General and corporate use	57.7	10.0%	13.9	43.8	Before December 31, 2026

Note:

(1) The expected timeline is based on the best estimation made by the Group on future market condition and may change with the future market condition and future development.

FUTURE DEVELOPMENT

We remain committed to advancing and expanding our product portfolio in therapeutic areas where we have accumulated deep expertise and extensive know-how.

LAE102 is our internally discovered monoclonal antibody targeting ActRIIA. Blocking Activin-ActRII pathway could promote muscle regeneration and reduce fat mass, positioning LAE102 as a promising drug candidate for muscle-preserving weight control. LAE103 is an ActRIIB-selective antibody and LAE123 is an ActRIIA/IIB dual antagonistic monoclonal antibody. Both are our internally discovered antibodies for muscle and other disease indications. The Group has established a comprehensive ActRII portfolio and strives to maximize the value of targeting ActRII receptors. Currently, we are rapidly advancing the clinical development of this portfolio while actively pursuing strategic partnerships to accelerate its overall development and commercialization.

In addition, the Group is actively exploring potential combination therapy opportunities across our pipeline, with existing approved drugs as well as conventional therapies. Our LAE002 (afuresertib) combination trial with fulvestrant has demonstrated remarkable clinical value in treating HR+/HER2- breast cancer patients who have failed previous standard of care treatments of endocrine/anti-estrogen therapies, including CDK4/6 inhibitors which represent a big unmet medical need with huge market potential. Similarly, our combination therapy of LAE002 (afuresertib) plus LAE001 has shown promising therapeutic benefits in patients with second-generation A/AR drug-resistant mCRPC. We remain committed to unlocking the full clinical potential of our drug candidates.

During the Reporting Period, the Group collaborated with Lilly to accelerate global clinical development of LAE102 for the treatment of obesity. In November 2025, we entered into an exclusive licensing agreement with Qilu Pharma to expedite the regulatory approval and commercialization of LAE002 (afuresertib) in the Licensed Territory and maximize its commercial value. Moving forward, we plan to pursue additional strategic partnerships with leading pharmaceutical companies to further advance the clinical development and commercialization of our drug candidate assets.

Looking ahead, the Group aims to achieve PCC declarations for LAE124 (DACRA) in 2026. In February 2026, we obtained IND approval from the U.S. FDA for LAE118, a PI3Kα pan-mutant selective inhibitor targeting PIK3CA-mutant solid tumors. Building on our proven track record of successfully developing and out-licensing LAE002 (afuresertib), we are accelerating the development of LAE118 with the goal of bringing this precision therapy to cancer patients in need of novel treatment options. Our expanding pipeline underscores our commitment to delivering life-changing therapies to patients worldwide.

CORPORATE GOVERNANCE RELATED INFORMATION

Compliance with Corporate Governance Code

The Company recognizes the importance of good corporate governance for enhancing the management of the Company as well as preserving the interests of the Shareholders as a whole. The Company has adopted the CG Code contained in Appendix C1 to the Listing Rules as its own code of corporate governance. The Directors are of the view that during the Reporting Period, the Company has complied with all applicable code provisions of the CG Code save and except for the following deviation from code provision C.2.1 of the CG Code.

Under code provision C.2.1 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Dr. LU Chris Xiangyang ("**Dr. Lu**") has served as our chairman since May 2018 and Chief Executive Officer since April 2017. Dr. Lu is the founder of our Group and has extensive experience in the business operations and management of our Group. Our Board believes that, in view of his experience, personal profile and his roles in our Company as mentioned, Dr. Lu is the Director best suited to identify strategic opportunities and focus of the Board due to his extensive understanding of our business as our Chief Executive Officer. Our Board also believes that the combined role of chairman and chief executive officer can promote the effective execution of strategic initiatives and facilitate the flow of information between management and the Board. Our Directors consider that the balance of power and authority will not be impaired due to this arrangement. In addition, all major decisions are made in consultation with members of the Board, including the relevant Board committees, and three independent non-executive Directors.

The Board will continue to review the effectiveness of the corporate governance structure of the Group in order to assess whether separation of the roles of chairman and the chief executive officer is necessary.

Compliance with the Model Code for Securities Transactions

The Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors and the Company's senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company or its securities.

Upon specific enquiry, all Directors confirmed that they have complied with the Model Code during the Reporting Period. In addition, the Company is not aware of any non-compliance of the Model Code by the employees of the Company who are likely to be in possession of inside information of the Company during the Reporting Period.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

On September 17, 2025, the Company completed a Placing of an aggregate of 36,000,000 placing shares by the sole placing agent to not less than six placees at a price of HK$16.30 per placing share pursuant to the terms and conditions of the Placing Agreement, representing approximately 8.06% of the issued share capital of the Company as enlarged by the allotment and issue of the placing shares immediately upon completion of the Placing.

The placing price of HK$16.30 per Placing Share was determined after arm's length negotiations between the Company and the Sole Placing Agent and represents (i) a discount of approximately 9.50% to the closing price of HK$18.01 per Share as quoted on the Stock Exchange on September 9, 2025, being the trading day immediately preceding the date of the Placing Agreement and (ii) a discount of approximately 4.0% to the average closing price of HK$16.98 per Share as quoted on the Stock Exchange for the five consecutive trading days of the Shares immediately preceding the date of the Placing Agreement.

The gross proceeds from the Placing were approximately HK$586.80 million. The Company received net proceeds from the Placing, after deducting the placing commission and other related expenses and professional fees, of approximately HK$577.51 million.

Further details of the Placing and the use of proceeds are set out in the announcements of the Company dated September 10, 2025 and September 17, 2025, respectively.

Save as disclosed above, neither the Company nor any of its subsidiaries purchased, redeemed or sold any of the Company's listed securities (including sale of treasury shares (as defined under the Listing Rules)) during the Reporting Period. As of December 31, 2025, the Company did not hold any treasury shares (as defined under the Listing Rules).

AUDIT COMMITTEE AND REVIEW OF ANNUAL RESULTS

The Company has established an Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the CG Code. The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of the Group, overseeing the audit process and performing other duties and responsibilities as assigned by the Board. The Audit Committee currently consists of two independent non-executive Directors being Mr. ZHOU Jian and Dr. LI Min, and one non-executive Director being Dr. WANG David Guowei. The chairperson of the Audit Committee is Mr. ZHOU Jian. Mr. ZHOU Jian holds the appropriate professional qualifications as required under Rules 3.10(2) and 3.21 of the Listing Rules.

The Audit Committee had reviewed, together with the management, the accounting principles and policies adopted by the Group and discussed internal controls and financial reporting matters including a review of the consolidated financial statements and annual results of the Group for the year ended December 31, 2025.

SCOPE OF WORK OF AUDITOR

The financial figures in respect of the Group's consolidated statement of profit or loss and other comprehensive income, consolidated statement of financial position and the related notes thereto for the year ended December 31, 2025 as set out in this announcement have been agreed by the Group's auditor, KPMG, Certified Public Accountants, to the amounts set out in the Group's consolidated financial statements for the year ended December 31, 2025. The work performed by KPMG in this respect did not constitute an assurance engagement and consequently no opinion or assurance conclusion has been expressed by KPMG on this announcement.

NO MATERIAL CHANGES

Saved as disclosed in this announcement, during the Reporting Period, there were no material changes affecting the Group's performance that needs to be disclosed under the Listing Rules.

EVENTS AFTER THE REPORTING PERIOD

Save as disclosed in this announcement and as at the date of this announcement, there were no material subsequent events after the Reporting Period.

FINAL DIVIDEND

The Board does not declare the payment of a final dividend to the Shareholders for the Reporting Period.

PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT

This announcement is published on the website of the Stock Exchange at www.hkexnews.hk and on the website of the Company at www.laekna.com. The annual report of the Company for the year ended December 31, 2025 containing all the information required by the Listing Rules will be published on the same websites and despatched (if requested) to the Shareholders in due course.

In this announcement, unless the context otherwise requires, the following expressions shall have the following respective meanings:

"AE"	adverse events, any untoward medical occurrences in a patient or clinical investigation subject administered a drug or other pharmaceutical product during clinical trials and which do not necessarily have a causal relationship with the treatment
"AKT"	a serine/threonine protein kinase with 3 isoforms (AKT1, AKT2 and AKT3) that participate in multiple pathways regulating several cellular processes, including survival, proliferation, tissue invasion, and metabolism
"Audit Committee"	the audit committee of the Board
"Board"	the board of directors of our Company
"CDE"	the center for drug evaluation of the NMPA
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"China", "Chinese Mainland" or "PRC"	the People's Republic of China, but for the purpose of this announcement and for geographical reference only and except where the context requires otherwise, references in this announcement to "China" and the "PRC" do not apply to Hong Kong Special Administrative Region of the People's Republic of China, Macau Special Administrative Region of the People's Republic of China and Taiwan, Province of China
"Company" or "our Company"	Laekna, Inc. (來凱醫藥有限公司), an exempted company incorporated in the Cayman Islands with limited liability on July 29, 2016
"Director(s)" or "our Director(s)"	the directors of the Company
"FDA"	the United States Food and Drug Administration
"Global Offering"	the Hong Kong Public Offering and the International Offering

"Group", "our Group", "we" or "our"	our Company and its subsidiaries
"HK$" or "HKD"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"HR+/HER2- breast cancer"	the most common type of breast cancer with overexpression of HR and without overexpression of HER2
"IHC"	immunohistochemistry, a test that uses a chemical dye to stain and measure specific proteins
"IND"	investigational new drug, the application for which is the first step in the drug review process by regulatory authorities to decide whether to permit clinical trials; also known as clinical trial application, or CTA, in China
"Listing"	the listing of the Shares on the Main Board of the Stock Exchange
"Listing Date"	June 29, 2023
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time
"mCRPC"	metastatic castration resistant prostate cancer
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
"MRCT"	multi-regional clinical trials
"NDA"	new drug application
"NMPA"	the National Medical Products Administration (國家藥品監督管理局) and its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局)

"Novartis"	Novartis Pharma AG, a company organized under the laws of Switzerland and one of our Pre-IPO Investors
"PCC"	pre-clinical candidate
"PD-1"	programmed cell death protein 1
"PFS"	progression-free survival, the length of time during and after the treatment of a disease, such as cancer, that a patient lives without the disease getting worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works
"Placing"	the placing of 36,000,000 placing shares pursuant to the terms of the Placing Agreement
"Placing Agreement"	the conditional placing agreement entered into between the Company and Merrill Lynch (Asia Pacific) Limited, the sole placing agent and sole overall coordinator of the Placing, dated September 10, 2025 in relation to the Placing
"PROC"	platinum resistant ovarian cancer
"Prospectus"	the prospectus of the Company dated June 16, 2023
"Reporting Period"	year ended December 31, 2025
"RMB"	Renminbi, the lawful currency of China
"rPFS"	radiographic progression free survival
"SAE"	serious AE, any medical occurrence in human drug trials that at any dose: results in death; is life-threatening; requires inpatient hospitalization or causes prolongation of existing hospitalization; results in persistent or significant disability/incapacity; may have caused a congenital anomaly/birth defect, or requires intervention to prevent permanent impairment or damage
"Share(s)"	ordinary share(s) in the share capital of our Company with a par value of US$0.00001 each

"Shareholder(s)"	holder(s) of Shares
"SOC"	treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by healthcare professionals
"South Korea"	the Republic of Korea
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"TEAE"	adverse events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment
"TNBC"	triple-negative breast cancer, any breast cancer that tests negative for estrogen receptors, progesterone receptors, and excess HER2
"treasury shares"	has the meaning as defined under the Listing Rules
"United States", "USA" or "U.S."	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"US$" or "USD"	United States dollars, the lawful currency of the United States
"%"	per cent

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, March 18, 2026

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.